Connect with us

Hi, what are you looking for?

Jewish Business News


David Levison revives his IPO plans for CardioDX

Levison originally planned  to float shares in the company  in November of last year.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

David Levison CardioDx

David  Levison, founder and CEO of Palo Alto based CardioDx, who specialize in cardiovascular genomic diagnostics, has announced his decision to reinstate the Initial public offering (IPO) originally planned for November of last year, which he put on ice citing the unfavorable market conditions that prevailed at that time.

When the prospect of an IPO  was initially raised, Levison was quoting as saying that he hoped to raise around $90 million, however this time around  the company are keepimg mum on how much they hope to raise..

What the recent filing does show is a dramatic increase in turnover  for  CardioDX in their last full financial year of 2013, up 300% from  2012. One the downside, howver,  the company’s  losses increased by around  44 percent during the period, reaching $36.9 million.


CardioDX has already succeeded in raising in excess of  $200 million in investor funding, led by  V-Sciences Investments, a wholly owned subsidiary of Temasek Life Sciences which hold just short of twenty percent  of shares in the company, followed by Menlo Park, California based life science investors Longitude Venture Partners, who hold 17.9 percent,  Artiman Ventures  with 13.9 percent, heavy duty venture capitalists,  Kleiner Perkins Caufield & Byers with 9.5 percent and JPMorgan Direct Venture Capital and MDV-Revelation holding around five percent each of the shares.

David Levison graduated with an  MBA from Stanford University later earning a Bachelor of Science degree from  Williams College, in Williamstown, Massachusetts.

Levison began his professional career with the Cole Gilburne Fund, an early stage, technology focused venture capital firm, leaving them to join the  Oncology Therapeutics Network , also serving as CFO of OTN’s parent company, Axion, from 1990 to 1993, leaving them in 1996, after the company was acquired by Bristol-Myers Squibb, one of the United States largest pharmaceutical companies,

After leaving Axion, David established  iScribe, a healthcare technology company which was acquired by AdvancePCS  in late 2001.

Before founding CardioDx in 2004, David spent some time as a Venture Partner at TPG Ventures.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News